|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer.
|
14723995 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The intratumoral and intertumoral variability in XIST RNA domain number in BRCA1 tumors correlates with chromosomal genetic abnormalities, including gains, losses, reduplications, and rearrangements of the X-chromosome.
|
17545591 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, distinct MIN-tumor-associated DNA amplifications were detected for E2F5 (8p22-q21.3), GARP (11q13.5-q14), ATM (11q22.3), KAL (Xp22.3), and XIST (Xq13.2) as well as DNA deletions for RAF1 (3p25), DCC (18q21.3), and KEN (21q tel). aCGH revealed distinct DNA copy number changes of oncogenes and tumor suppressor genes in CIN- and MIN-type sporadic colorectal carcinomas.
|
17143621 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, the significant higher levels of XIST-RNA detected in BRCA1-associated respect to sporadic basal-like cancers, opens the possibility to use XIST expression as a marker to discriminate between the two groups of tumors.
|
19440381 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, the XIST and lncRNA-XIST expression correlation between tumor tissues and plasma was demonstrated by linear regression analysis.
|
26339353 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The in vivo studies also showed that knockdown of XIST suppressed tumor growth and produced high survival in nude mice.
|
25578780 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In previous studies, high expression of XIST and low expression of 53BP1 were respectively associated with poor systemic therapy outcome in patients and therapy resistance in BRCA1-deficient mouse tumor models, but have not been evaluated in BRCA1-deficient patients.
|
26637364 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Functionally, knockdown of lncRNA XIST exerted tumor-suppressive effects by inhibiting cell proliferation, migration and invasion in vitro and tumor growth and metastasis in vivo.
|
27620004 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In our research, lncRNA-XIST was specifically upregulated in PC tissues and cell lines, and high XIST expression in PC was related to poorer prognosis (larger tumor size, perineural invasion, lymph node micrometastases, and shorter overall survival).XIST augmented PC cell proliferation.
|
28295543 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, XIST knockdown significantly inhibited bladder cancer cell growth and metastasis <i>in vitro</i> and tumor growth <i>in vivo</i>.
|
29212249 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that XIST was significantly up-regulated in osteosarcoma tissues and cell lines, and high XIST expression was significantly associated with advanced tumor size (p=0.009), advanced clinical stage (p=0.001) and present distant metastasis (p=0.009).
|
28682435 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicated that XIST functioned as a tumor suppressor in OS.
|
29048648 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Low expression of XIST was correlated with poor prognosis and advanced tumor stage in prostate cancer patients.
|
29212233 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) is involved in the progression of several tumors.
|
28869948 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings indicated that XIST may regulate the tumor growth and metastasis via miR-140-dependent iASPP regulation.
|
28656261 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that XIST plays a critical role in brain metastasis in breast cancer by affecting both tumor cells and the tumor microenvironment and that the XIST-mediated pathway may serve as an effective target for treating brain metastasis.<b>Significance:</b> These findings describe mechanisms of how loss of the lncRNA XIST promotes brain metastasis in breast cancer and identify fludarabine as a potential therapeutic agent that specifically eliminates XIST<sup>low</sup> tumor cells in the brain.<i></i>.
|
30026327 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
For clinicopathological parameters, MALAT1 expression was significantly associated with lymph node metastasis (OR = 2.731; 95% CI: 1.409-5.292; <i>p</i> = 0.003), and high-level expression of XIST was related to larger tumor size (OR = 2.473; 95% CI: 1.159-5.276; <i>p</i> = 0.019) and higher TNM stage (OR = 0.400; 95% CI, 0.184-0.868; <i>p</i> = 0.020).
|
29899709 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
JPX knock-in significantly increased XIST expression and inhibited HepG2 cell growth in vitro or tumor formation in vivo in a XIST dependent manner.
|
30091314 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, silencing of XIST could inhibit tumor growth in vivo.
|
29227532 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The lncRNA X inactive specific transcript (XIST) is a potential tumour suppressor in some types of cancers.
|
29550489 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Xenograft tumor assay was used to verify the role of XIST in DOX resistance in CRC in vivo.
|
30439718 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results showed that expression level of XIST was markedly associated with overall survival (function as oncogene, HR = 0.53, 95% CI: 0.42-0.68, <i>p</i> < 0.00001; function as tumor suppressor, HR = 2.25, 95% CI: 1.15-4.37, <i>p</i> = 0.02), disease free survival (DFS)(HR = 0.45; 95% CI: 0.31-0.67, <i>p</i> < 0.0001), tumor type (digestive system carcinoma, HR = 0.50; 95% CI: 0.37-0.69, <i>p</i> < 0.00001; non-digestive system carcinoma, HR = 0.58; 95% CI: 0.39-0.87, <i>p</i> = 0.008), lymph node metastasis (OR = 0.32, 95% CI: 0.20-0.52, <i>p</i> < 0.00001), distant metastasis (OR = 0.36, 95% CI: 0.22-0.60, <i>p</i> < 0.0001) and tumor stage (OR = 0.43, 95% CI: 0.31-0.60, <i>p</i> < 0.00001).
|
29568404 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides, XIST knockdown inhibited tumor growth in vivo.
|
29679755 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This meta-analysis demonstrated that elevated lncRNA XIST expression predicts poor OS, poor DFS, larger tumor size, increased distant metastasis and advanced tumor stage, suggesting that high lncRNA XIST expression may serve as a novel biomarker for poor prognosis and metastasis in cancers.
|
29307668 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
XIST is dysregulated and acts as an oncogene or a tumor suppressor in different human malignancies.
|
30171939 |
2018 |